Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Limited (ASX: NEU)
Latest News
Share Gainers
Why Cooper Energy, Medibank, NAB, and Neuren shares are charging higher today
Share Gainers
Why Azure Minerals, Global Lithium, Mesoblast, and Neuren shares are racing higher
Healthcare Shares
Why is the Neuren Pharmaceuticals share price rocketing 26% on Friday?
Share Gainers
These were the 5 top-performing ASX All Ords shares of FY23
Share Market News
2 ASX 300 directors sold over $15 million of their company shares this week
Broker Notes
These 3 ASX shares are in the buy zone right now
Investing Strategies
The top 10 ASX shares held by millionaires
Share Gainers
Why Core Lithium, Neuren, Norwest, and Pilbara Minerals shares are pushing higher
Opinions
Why this fund manager thinks these 2 outperforming ASX shares can keep beating the market
Share Gainers
Why Corporate Travel Management, Kingsgate, Liontown, and Neuren shares are racing higher
Record Highs
2 ASX 300 shares cracking record highs on Friday
Share Gainers
Why Atlantic Lithium, Life360, Neuren, and Whitehaven Coal shares are charging higher
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
